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(CB) are associated with higher recurrence rates after ablation
therapy for atrial ﬁbrillation (AF).
OBJECTIVE Thus far, there are no reports on the quantiﬁcation of
the extensiveness of CD and CB at the pulmonary vein area (PVA)
and their clinical relevance.
METHODS Intraoperative high-density epicardial mapping of the
PVA (interelectrode distance 2 mm) was performed during sinus
rhythm in 268 patients (mean 6 SD [minimum–maximum] 67 6
11 [21–84] years) with and without preoperative AF. For each pa-
tient, extensiveness of CD (conduction velocity 17–29 cm/s) and
CB (conduction velocity ,17 cm/s) was assessed and related to
the presence and type of AF.
RESULTS CD and CB occurred in, respectively, 242 (90%) and 183
(68%) patients. Patients with AF showed a higher incidence of
continuous conduction delay and block (CDCB) lines (AF: n 5 37
[76%]; no AF: n 5 132 [60%]; P 5 .046), a 2-fold number of lines
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licenses/by-nc-nd/4.0/).[0–12], P5 .003; CDCB: 2 [0–6] vs 1 [0–8], P5 .004), and a higher
incidence of CD or CB lines 6 mm and CDCB lines 16 mm
(P 5 .011, P 5 .025, and P 5 .027). The extensiveness of CD,
CB, and CDCB could not distinguish between the different AF types.
CONCLUSION Patients with AF more often present with continuous
lines of adjacent areas of CD and CB, whereas in patients without AF,
lines of CD and CB are shorter and more often separated by areas
with normal intra-atrial conduction. However, a considerable over-
lap in the amount of conduction abnormalities at the PVA was
observed between patients with a history of paroxysmal and persis-
tent AF.
KEYWORDS Atrial ﬁbrillation; Conduction; Epicardial mapping; Pul-
monary veins; Sinus rhythm
(Heart Rhythm 2018;-:1–9) © 2018 The Authors. Published by
Elsevier Inc. on behalf of Heart Rhythm Society. This is an open ac-
cess article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The pulmonary vein area (PVA) has been of particular inter-
est in the pathophysiology of atrial ﬁbrillation (AF) ever
since Haïssaguerre et al1 demonstrated bursts of rapid ectopic
beats as triggers for spontaneous AF. Since then, treatment
strategies for AF mainly focus on the isolation of the PVA
by endocardial and/or epicardial ablation. Yet, recurrence
rates are considerable for both patients with paroxysmal AF
and those with persistent AF and are likely the result of either
reconduction or transition of AF from a trigger-driven to a
more substrate-driven disease.2To date, AF recurrences after ablation procedures remain
difﬁcult to predict. Yet, ﬁbrosis at the left atrial (LA) poste-
rior wall, resulting in conduction delay (CD) or conduction
block (CB), appears to be associated with higher recurrence
rates.3,4 It has been suggested that the assessment of
electropathology, including low voltages, fractionation, and
conduction abnormalities, during sinus rhythm (SR) at the
PVA may facilitate the identiﬁcation of target sites for
ablation or can be used to predict AF recurrences after
ablation therapy.5–9
In several mapping studies, a line of CB running vertically
between the right and left pulmonary veins during SR was
identiﬁed.10–12 This CB line varied between patients in its
continuity and could in some patients be altered by pacing,
indicating that it was partly functional in nature.10–12
Furthermore, this line was more frequently observed in
patients with AF or mitral valve regurgitation.11,12 On the
basis of histological ﬁndings in postmortem hearts, the
authors suggested that abnormal conduction was the result
of a change in myocardial ﬁber direction.10 Aside from thisythm Society.
mons.org/
https://doi.org/10.1016/j.hrthm.2018.10.027
Figure 1 Mapping of the pulmonary vein area. Upper panels:Mapping of the pulmonary vein area with a 192-electrode array and the corresponding electro-
grams recorded during 5 seconds of sinus rhythm. Lower panels: Schematic view of the pulmonary vein area (left) and activation maps and CD/CB map (right)
(blue lines, CD; red lines, CB). A5 atrial, CB5 conduction block; CD5 conduction delay; ICV5 inferior caval vein; LAA5 left atrial appendage; LI5 left
inferior; LS 5 left superior; PVL 5 pulmonary vein left; PVR 5 pulmonary vein right; RI 5 right inferior; RS 5 right superior; SCV 5 superior caval vein;
V 5 ventricular.
2 Heart Rhythm, Vol-, No-,- 2018line of CB, other areas of conduction disorders were observed
in only a minority of patients.10–12 However, the degree and
extent of conduction abnormalities during SR at the PVA
have never been quantiﬁed and correlated with the different
types of AF as deﬁned by the European Society of
Cardiology guidelines.13 The goals of the present intraopera-
tive high-resolution epicardial mapping study were therefore
to detect and quantify conduction abnormalities at the PVA in
a large cohort of patients during SR and to investigate the as-
sociation with AF persistence.Methods
Study population
The study population consisted of 268 successive adult pa-
tients undergoing elective coronary artery bypass grafting,
aortic or mitral valve surgery, or a combination of valvular
and bypass grafting surgery. This study was approved by
the institutional medical ethical committee (MEC2010-054/
MEC2014-393). Written informed consent was obtained
from all patients, and clinical data were extracted from elec-
tronic patient ﬁles. A detailed description of the methods is
provided in the Supplemental Material.Epicardial high-resolution mapping
Epicardial high-resolution mapping of the PVA was per-
formed during SR from the transverse sinus along the borders
of the right and left pulmonary veins down toward the atrio-
ventricular groove (Figure 1), as previously described.14
Local activation maps of the right and left pulmonary
veins during SR were constructed by annotating the steepest
negative slope of atrial potentials recorded at every electrode
(see also Supplemental Figure 1). Heterogeneity in conduc-
tion was determined by quantifying the amount, number,
and length of lines of CD, CB, and continuous conduction
delay and block (CDCB) and its differences between patient
groups on a 2 mm resolution scale. Lines of CD and CB were
deﬁned as time differences (Dt) of, respectively, 7–11 and
12 ms between adjacent electrodes.15,16Statistical analysis
Normally distributed data are presented as mean6 SD (min-
imum–maximum). Skewed data are presented as median
(minimum; interquartile range; maximum) and analyzed us-
ing Mann-Whitney U tests. Categorical data are expressed
as numbers and percentages and analyzed using the c2 test
Table 1 Patient characteristics (N 5 268)
Characteristic Value
Age (y) 67 6 11 (21–84)
Sex: male 196 (73)
BMI (kg/m2) 28 6 5 (18–55)
Underlying heart disease
IHD 157 (59)
(i)VHD 111 (41)
Aortic valve stenosis 69 (26)
Aortic valve insufﬁciency 6 (2)
Mitral valve insufﬁciency 36 (13)
Left atrial dilation .45 mm 58 (22)
History of AF 49 (18)
Paroxysmal 38 (14)
Persistent 11 (4)
Left ventricular function
Normal 203 (76)
Mild dysfunction 52 (19)
Moderate dysfunction 11 (4)
Severe dysfunction 2 (1)
Antiarrhythmic drugs 197 (74)
Class I 2 (1)
Class II 183 (68)
Class III 12 (5)
Class IV 3 (1)
Values are presented as mean 6 SD (minimum–maximum) or as n (%).
BMI 5 body mass index; IHD 5 ischemic heart disease; (i)
VHD 5 ischemic and valvular heart disease; VHD 5 valvular heart disease.
Mouws et al Conduction Abnormalities at the PVA 3or Fisher exact test, as appropriate. Receiver operating char-
acteristic curves for the difference in CD and CB lengths
were constructed, and cutoff values were based on sensitivity
. 50% and 1 2 speciﬁcity , 50%. Multivariate regression
analysis was performed to identify independent predictors
of CD and CB. A P value of,.05 was considered statistically
signiﬁcant.Results
Study population
The characteristics of the study population (N 5 268;
196 men [73%]; mean [minimum–maximum] age 67 6 11
[21–84] years; mean [minimum–maximum] body mass index
[BMI] 286 5 [18–55] kg/m2) are summarized in Table 1. Pa-
tients had either ischemic heart disease (IHD) (n 5 157
[59%]) or ischemic and valvular heart disease ((i)VHD)
(n 5 111 [41%]; only valvular disease: n 5 63 [24%]). LA
dilation was present in 58 patients (22%) and 49 patients
(18%) had a history of AF.Most patients had normal left ven-
tricular function (n 5 203 [76%]) and used class II antiar-
rhythmic drugs (n 5 183 [68%]).Incidence of CD and CB
Most patients showed lines of CD (n 5 242 [90%]) and CB
(n5 183 [68%]) at the PVA during SR. The number of lines
of CD (4 [0–30]) was signiﬁcantly higher than that of CB
lines (1 [1–12]) (P , .001), though the maximum length of
CB lines was longer (median [minimum; interquartile range;
maximum], CD: 6 [2; 4–10; 20] mm; CB: 8 [2; 4–12; 44]mm; P, .001) (Figure 2). A clear turning point was observed
at a length of 8 mm from which point on the incidence of
CB lines exceeded the incidence of CD lines. Most patients
also had continuous lines of CDCB (n5 169 [63%]; median
number 1 [0–6]; maximum length 14 [4–72] mm).
A longitudinal line of CD or CB running vertically be-
tween the left and right pulmonary veins from superior to
inferior positions was observed in 14 patients (5%), though
varying in its continuity and length. Typical examples of acti-
vation maps and corresponding isochrones and CD/CB maps
of these patients are shown in Figure 3. The incidence of this
line was similar between patients without and with AF
(P 5 .295), as well as between patients with IHD and those
with (i)VHD (P 5 .503). However, this line was more often
observed in patients with LA dilation (n 5 6 [10%]) than in
patients without LA dilation (n5 8 [4%]) (P5 .048). As dis-
played in Table 2, multivariate regression analysis revealed
only the presence of AF episodes as an independent predictor
of long lines of CD and CB at the PVA; clinical characteris-
tics including IHD, (i)VHD, LA dilation, sex, BMI, older
age, and left ventricular dysfunction were not.Association between AF and heterogeneity in
conduction
The upper panel of Figure 4 displays typical examples of acti-
vation maps and the corresponding CD/CB maps obtained
from a patient without AF and a patient with AF.
Patients with AF more often have continuous lines of
CDCB as compared with patients without AF, as demon-
strated in the middle left panel (AF: n 5 37 [76%]; no AF:
n 5 132 [60%]; P 5 .046).
The number of lines of CD, CB, and CDCB in patients
with AF was approximately 2-fold the number observed in
patients without AF (CD: 7 [0–30] vs 4 [0–22], P , .001;
CB: 3 [0–11] vs 1 [0–12], P 5 .003; CDCB: 2 [0–6] vs 1
[0–8], P 5 .004).
As demonstrated in Figure 4, the incidence of both CD and
CB lines 6 mm was higher in patients with AF than in pa-
tients without AF (CD: 69% [n 5 34] vs 49% [n 5 108],
P 5 .011; CB: 59% [n 5 29] vs 42% [n 5 91], P 5 .025).
The maximum length of continuous CDCB lines in
patients with AF ranged from 8 to 72 mm, whereas in patients
without AF this length ranged from 4 to 42 mm; CDCB lines
16 mm occurred more often in patients with AF (n 5 20
[41%] vs n 5 50 [25%]; P 5 .027).
Hence, the presence of AF episodes was strongly associ-
ated with increased heterogeneity in conduction, marked
not only by a higher incidence of CB and CDCB but also
by a higher number of lines of CD, CB, and CDCB and
more importantly longer lines of CD, CB, and CDCB.
Thus, patients with AF more often present with contin-
uous lines of adjacent areas of CD and CB, whereas in pa-
tients without AF, lines of CD and CB are more often
separated by areas with normal intra-atrial conduction. These
ﬁndings were validated in an age- (5-year range),
Figure 2 Characteristics of CD and CB. Activationmaps showing the typical difference between lines of CD (blue lines) and lines of CB (red lines): lines of CB
occur less frequently, yet extend over longer lengths. A turning point was observed at a length of 8 mm, as displayed in the lower panel. Color classes per 10 ms.
CB 5 conduction block; CD 5 conduction delay.
4 Heart Rhythm, Vol-, No-,- 2018BMI- (2-kg/m2 range), sex-, and type of surgery–matched
case-control analysis (AF N=35, No AF N=35).
In addition, patients who developed de novo AF in the
early postoperative phase (70 patients without preoperative
AF [32%]) showed a trend toward more CB lines
(P 5 .055), a higher number of continuous CDCB lines
(P5 .030) at the PVA, and a trend toward a higher incidence
of long CB lines (.6 mm) (P 5 .073).Severity of conduction abnormalities vs clinical AF
classiﬁcation
Figure 5 provides typical examples of PVA activation com-
bined with the corresponding CD and CB maps obtained
from 2 patients with paroxysmal AF and 2 patients with
persistent AF; the amount of conduction abnormalities in 1
patient with paroxysmal AF is even higher than in the patient
with persistent AF.
Figure 5 shows that there is a large interindividual varia-
tion in the amount of conduction abnormalities in both parox-
ysmal and persistent AF groups. There is also no difference
between patients with paroxysmal AF and patients with
persistent AF in the number of CD, CB, and CDCB lines
(P 5 .442, P 5 .535, and P 5 .951). Also, incidences of
CD, CB, and CDCB were similar (P 5 .204; P 5 .835,
and P 5 .708); receiver operating characteristic curve ana-
lyses could not identify a cutoff value for the length of lines
distinguishing patients with persistent AF from those with
paroxysmal AF. The duration of AF history was similar forpatients with paroxysmal AF and those with persistent AF
(P 5 .429).
Hence, although this is only a small group of patients, the
overlap in the severity of conduction abnormalities suggests
that severity of conduction abnormalities at the PVA does not
seem to clearly differentiate patients with paroxysmal AF
from patients with persistent AF.Discussion
Key ﬁndings
Intraoperative high-resolution epicardial mapping of the
PVA during SR for the ﬁrst time quantiﬁed and characterized
different types of conduction abnormalities and related it to
the presence of AF episodes. Current data demonstrated
that patients with AF have more and longer lines of CD,
CB, and CDCB, whereas in patients without AF, short lines
(,6 mm) of CD and CB separately are more diffusely pre-
sent. Furthermore, the severity of conduction abnormalities
at the PVA during SR does not differentiate between patients
with paroxysmal AF and those with persistent AF.
Conduction abnormalities at the PVA
To our knowledge, only 3 previous studies have investi-
gated conduction abnormalities at the posterior wall of the
LA in humans during SR. In an endocardial noncontact
mapping study by Markides et al,10 conduction at the LA
was analyzed during SR in 19 patients with a history of
paroxysmal AF. They observed a vertical line of CB (inter-
electrode time interval 30 ms) extending from the LA roof
Figure 3 Longitudinal line of CD/CB between the right and left pulmonary veins. Typical examples of activation maps with a line of CD (blue lines), CB (red
lines), or CDCB running downward between the right and left pulmonary veins, though varying in its continuity. Corresponding isochrone maps (per 5 ms) and
CD/CB maps are shown next to the activation maps. Arrows indicate the main wave trajectory; local activation times are provided next to the arrows. Lightning
bolts indicate areas of simultaneous activation. Color classes per 10 ms. CB5 conduction block; CD5 conduction delay; CDCB5 continuous conduction delay
and block.
Mouws et al Conduction Abnormalities at the PVA 5across the posterior LA wall turning septally below the
ostium of the right inferior pulmonary vein proceeding ante-
riorly toward the septal mitral annulus.10 This CB line was
present in all patients, though varied in its continuity, partic-
ularly during pacing from different sites.10 In a minority of
patients, the CB line disappeared completely duringpacing.10 On the basis of histological ﬁndings in postmor-
tem hearts, Markides et al10 suggested that the line of CB
was caused by an abrupt change in myocardial ﬁber orien-
tation at the subendocardium.
Roberts-Thomson et al11 performed epicardial mapping
during SR in 34 patients without AF. They observed a similar
Table 2 Analysis of risk factors for CD and CB maximum length in the upper 50th percentile
Variable
CD CB
OR 95% CI P OR 95% CI P
Univariate analysis
Age (per y) 1.026 0.999–1.053 .060 1.005 0.982–1.028 .700
Sex: male 0.602 0.339–1.067 .082 0.961 0.547–1.688 .891
(i)VHD 1.183 0.696–2.011 .535 0.797 0.478–1.330 .386
IHD 0.846 0.497–1.437 .535 1.254 0.752–2.093 .386
LA dilation 1.347 0.725–2.503 .346 0.702 0.373–1.319 .271
LVF (compared with normal function)
Mild dysfunction 1.390 0.726–2.659 .320 1.162 0.620–2.179 .640
Moderate dysfunction 1.500 0.423–5.322 .530 0.697 0.179–2.711 .603
Severe dysfunction 2.625 0.161–42.69 .498 1.859 0.115–30.17 .663
AF history 2.082 1.097–3.950 .025 1.630 0.869–3.057 .128
Multivariate analysis
Age (per y) 1.020 0.993–1.048 .139
Sex: male
(i)VHD
IHD 1.370 0.792–2.370 .260
LA dilation 0.670 0.347–1.292 .232
LVF (compared with normal function)
Mild dysfunction
Moderate dysfunction
Severe dysfunction
AF history 1.872 0.971–3.609 .061 1.967 1.005–3.851 .048
Hosmer and Lemeshow estimate 0.808 0.778
AF 5 atrial ﬁbrillation; CB 5 conduction block; CD 5 conduction delay; CI 5 conﬁdence interval; IHD 5 ischemic heart disease; (i)VHD 5 ischemic and
valvular heart disease; LA 5 left atrial; LVF 5 left ventricular function; OR 5 odds ratio.
6 Heart Rhythm, Vol-, No-,- 2018line of functional CD, deﬁned as a conduction velocity be-
tween 10 and 20 cm/s, running vertically across the PVA,
though only occurring in a minority of 5 patients.11 In
contrast to the ﬁndings of Markides et al, during pacing
from superior and inferior positions at the PVA, the line of
CD now appeared in all patients.11
In a subsequent study, epicardial SR mapping after elec-
trocardioversion in 16 patients without AF and 5 patients
with persistent AF showed a similar vertical CD line in 2 pa-
tients without AF whereas this was observed in 4 patients
with AF.12 However, when pacing from different sites, the
CD line again appeared in all patients without AF and the
number of CD lines increased in patients with AF to a
maximum of 3 vertical lines running parallel to each other
across the PVA.12 Although the ﬁndings of Markides et al
and Roberts-Thomson et al appear to contradict each other,
it may be concluded that this line of CD was more evident
in patients with AF and was, at least in part, functional, as
it varied during different pacing conditions. Besides the ver-
tical line of abnormal conduction, no other CD/CB lines were
observed in these studies.
In contrast to these previous studies, we observed conduc-
tion abnormalities scattered across the PVAwith no clear pre-
dilection site. Lines of CD occurred in almost all patients and
CB in approximately 70% of the population. The fact that the
aforementioned studies did not observe any other lines of CD
or CB at the PVA is remarkable, especially since study pop-
ulations consisted of patients with IHD, patients with AF, and
patients with LA dilation due to mitral regurgitation. In allthese patients, areas of ﬁbrosis would be expected, particu-
larly at the LA posterior wall. Our CB criteria correspond
with a conduction velocity of,17 cm/s, which is in the range
of the CD criteria of Roberts-Thomson et al. Therefore,
although our cutoff criteria are slightly more sensitive, the
higher incidence of CD/CB cannot be totally explained by
differences in cutoff values. Yet, the higher resolution of
the mapping system used in the present study may be the
explanation for this discrepancy, as it contains the unique
ability to identify lines of CD and CB with a minimum length
of 2 mm. Furthermore, we did not set a minimum length or
wavefront propagation criterion for lines of CD and CB, as
opposed to previous studies.
In our cohort, only a minority of patients showed a longi-
tudinal line running downward between the left and right pul-
monary veins, which might be similar to the line observed in
previous studies. However, this line varied in length and con-
tinuity and practically never consisted of a line of CB running
continuously from the superior to the inferior of the posterior
wall. The precise nature of this line so far remains unclear. If,
as suggested by previous studies, a histological change in ﬁ-
ber direction would be the underlying cause, we would
expect it to occur in the majority of patients during SR.Conduction abnormalities and AF
In correspondence to previous studies, increased amounts of
CD, CB, and CDCB at the PVA were observed in patients
with AF. In patients with AF, a higher incidence of CB,
Figure 4 Differences in electropathology between patients without and with AF. Upper panels: Typical examples of activation maps of a patient without AF
and a patient with AF.Middle and lower panels: Patients with AF show more electropathology at the pulmonary vein area. Patients with AF particularly show a
higher incidence of CB and CDCB, a higher number of CD, CB, and CDCB lines per patients, and also longer lengths of CD (blue lines), CB (red lines), and
CDCB lines. Color classes per 10ms. AF5 atrial ﬁbrillation; CB5 conduction block; CD5 conduction delay; CDCB5 continuous conduction delay and block.
Mouws et al Conduction Abnormalities at the PVA 7CDCB, and an almost 2-fold number of separate CD, CB, and
CDCB lines per patient was observed. Also, CD, CB, and
CDCB lines extended over larger areas.
These observations suggest a critical role for the spatial
distribution of conduction abnormalities in AF development.
A certain length of an area of abnormal conduction is required
for reentry to occur; this phenomenon was ﬁrst demonstrated
by Ortiz et al17 in 7 canine hearts with sterile pericarditis. In
this study, the critical role of the length of an area of functional
block in the right atrial free wall was observed. In the case ofstable atrial ﬂutter, a functional CB line of 24 mm was
observed, enabling reentry to occur.17 When the cycle length
decreased, areas of slow conduction disappeared, resulting in
a shorter line of functional CBwith amean length of 16mm.17
This resulted in unstable reentrant circuits migrating across
the atrial wall, giving rise to AF.17 When the atrial wall
already contains continuous long lines of structural CD and
CB, it is likely more vulnerable to reentry circuits to occur
or for areas of functional block to connect, thereby reaching
the critical length for AF initiation.
Figure 5 Overlap in electropathology between paroxysmal AF and persistent AF. Upper left panel: Activation maps of a patient with ischemic heart disease
and a patient with valvular heart disease with paroxysmal AF, both diagnosed 3months before surgery. The corresponding CD/CBmaps (blue lines, CD; red lines,
CB) show a relatively small amount of CD/CB in the ﬁrst patient, whereas the second patient has a large amount of CD/CB.Upper right panel:Activationmaps of
patients with persistent AF. Both patients underwent mitral valve surgery and were diagnosed with persistent AF, respectively, 3 and 6 months before surgery;
both patients underwent electrocardioversion to sinus rhythm before mapping. In this case also, one patient has a relatively small amount of electropathology,
whereas the other patient has a large amount of CD/CB. Hence, a considerable overlap in the amount of conduction disorders is observed between paroxysmal
AF and persistent AF, which is also quantiﬁed in the lower panel, showing the number of lines per patient and the distribution of lengths of these lines. Color
classes per 10 ms. AF 5 atrial ﬁbrillation; CB 5 conduction block; CD 5 conduction delay; CDCB 5 continuous conduction delay and block.
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Despite the fact that conduction abnormalities are more pro-
found in patients with AF, the clinical categories of AF do not
correspond with the amount of conduction disorders at the
PVA during SR. In a previous study, we demonstrated a
considerable intra-atrial variation in the distribution of con-
duction disorders across the right atrium and LA, indicating
that a low amount of CB at the PVA does not necessarily
implicate a low amount of CB at other atrial regions.18Hence, either the arrhythmogenic substrate underlying AF
is not located at the PVA in these patients or, although CD
and CB measured during SR are indicators of structural con-
duction abnormalities, functional conduction disorders may
only be revealed during triggers or AF.
To date, ablation treatment strategies for AF focus primar-
ily on isolation of the pulmonary veins.
However, recurrence rates remain unsatisfactory. Recent
studies have shown the complex and heterogeneous etiology
Mouws et al Conduction Abnormalities at the PVA 9of fractionated potentials, providing a possible explanation of
the low success rate of ablation therapy targeting these com-
plex fractionated potentials.19
Furthermore, recent studies have revealed that aside from
the well-known effects of increased renin-angiotensin-system
activation, cardiac endothelin-1 levels may play an in impor-
tant role in AF pathogenesis.20 Endothelin-1 expression, pro-
moting myocyte hypertrophy and interstitial ﬁbrosis, was
increased during AF compared to SR.20 Particularly,
endothelin-1 levels were higher at the LA and in patients
withVHD, leading to the presumption that thismay play a sub-
stantial role in the vulnerability of these patients for AF devel-
opment.20 Also, increased endothelin-1 levels are regarded as
an important factor inAF persistence. As endothelin-1 produc-
tion is stretch mediated, atrial regions subjected to greater wall
stress may also produce higher levels of endothelin-1, thereby
leading to regional differences in conduction abnormalities.20
Study limitations
Whether general anesthesia inﬂuences conduction is yet to be
investigated; however, as a standard anesthetic protocol was
used for all patients, equal dispersion of possible effects can
be assumed. The number of patients with AF was relatively
small; thereby, when comparing patients with persistent and
paroxysmal AF, conclusions should be drawn cautiously. In
addition, although late gadolininum enhancement- magnetic
resonance imaging (LGE-MRI) is a feasible technique to detect
cardiac ﬁbrosis, it was logistically and ﬁnancially not possible
to perform LGE-MRI before surgery in these patients.
Conclusion
Intraoperative high-resolution epicardial mapping of the PVA
during SR for the ﬁrst time quantiﬁed and characterized
different types of conduction abnormalities and demonstrated
that the presence ofAF episodes is associatedwith continuous
lines of adjacent areas of CD and CB, whereas in patients
without AF, lines of CD and CB are shorter and more often
separated by areas with normal intra-atrial conduction. Pa-
tients with AF showed a 2-fold number of CD, CB, and
CDCB lines per patient, which also extended over longer
lengths. This study demonstrated a considerable overlap in
the amount of conduction abnormalities at the PVA between
patients with a history of paroxysmal and persistent AF.
Studies quantifying the extensiveness of electropathology
by various parameters, including conduction abnormalities,
may contribute to the future development of a more accurate
risk estimation of recurrent AF after ablation therapy and will
thereby enable more patient-tailored care in the future.
Appendix
Supplementary data
Supplementary data associated with this article can be found
in the online version at https://doi.org/10.1016/j.hrthm.2
018.10.027.References
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